Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists wire up pelvic nerves to decode bladder and bowel disorders

NCT ID NCT05200923

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to collect electrical signals from the body in people with overactive bladder, fecal incontinence, or urinary retention who are receiving sacral neuromodulation therapy. Researchers will gather data at several time points during the evaluation period to better understand how the therapy affects nerve signals. The study involves 300 participants and is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sacral neuromodulation device
What this could lead to
If successful, this could improve understanding of how sacral neuromodulation works, potentially leading to better therapies for pelvic health conditions.
What could go wrong
This is an observational data-collection study, not a treatment trial. It is early-stage and may not directly lead to new treatments or benefits for participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Overactive Bladder Criteria Inclusion Criteria 1. 18 years of age or older 2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication\* requiring an advanced evaluation 3. Willing and able to provide signed and dated informed consent 4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol 5. Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation 6. For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in the first 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion) of the voiding diary. 7. For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day within the first 72 hours of the voiding diary. Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Non-Obstructive Urinary Retention Inclusion Criteria 1. 18 years of age or older 2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication\* requiring an advanced evaluation 3. Willing and able to provide signed and dated informed consent 4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol 5. Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation 6. Have a diagnosis of non-obstructive urinary retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions. Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Fecal Incontinence Inclusion Criteria 1. 18 years of age or older 2. Candidate for or undergoing Medtronic InterStim lead implant labeled indication\* requiring an advanced evaluation 3. Willing and able to provide signed and dated informed consent 4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol 5. Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation 6. Have a diagnosis of fecal incontinence as demonstrated by 3-day a bowel diary as greater than or equal to 1 incontinent episode of more than staining (i.e., either slight, moderate, or severe soiling) Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Exclusion Criteria: Overactive Bladder Criteria Exclusion Criteria 1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) 2. Implanted with a neurostimulator, pacemaker or defibrillator 3. Pelvic floor muscle dysfunction due to surgical intervention or injury 4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) 5. History of diabetes unless the diabetes is well-controlled through diet and/or medications 6. Have symptomatic urinary tract infection (UTI) 7. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component 8. Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study 9. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months 10. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study 11. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy 12. Women who are pregnant or planning to become pregnant 13. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture) 14. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements Non-Obstructive Urinary Retention Exclusion Criteria 1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) 2. Implanted with a neurostimulator, pacemaker or defibrillator 3. Pelvic floor muscle dysfunction due to surgical intervention or injury 4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) 5. History of diabetes unless the diabetes is well-controlled through diet and/or medications 6. Have symptomatic urinary tract infection (UTI) 7. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months 8. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study 9. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy 10. Women who are pregnant or planning to become pregnant 11. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture) 12. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements Fecal Incontinence Exclusion Criteria 1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) 2. Implanted with a neurostimulator, pacemaker or defibrillator 3. Pelvic floor muscle dysfunction due to surgical intervention or injury 4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) 5. Have uncorrected high grade internal rectal prolapse 6. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months 7. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study 8. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy 9. Women who are pregnant or planning to become pregnant 10. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fecal incontinence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fecal Incontinence overactive bladder Urinary Retention

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • DHR Health Institute for Research and Development

    COMPLETED

    Edinburg, Texas, 78539, United States

  • Indiana University Health Methodist Research Institute

    RECRUITING

    Indianapolis, Indiana, 46202, United States

  • LSUHSC Department of Urology

    WITHDRAWN

    New Orleans, Louisiana, 70112, United States

  • Mayo Clinic Urology/Urogynecology Department

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Ochsner Clinic Foundation

    RECRUITING

    New Orleans, Louisiana, 70121, United States

  • OhioHealth Physician's Group Urology

    RECRUITING

    Hilliard, Ohio, 43026-2050, United States

  • University Hospitals Cleveland Medical Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.